76 related articles for article (PubMed ID: 20184933)
1. Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems.
Rothdiener M; Müller D; Castro PG; Scholz A; Schwemmlein M; Fey G; Heidenreich O; Kontermann RE
J Control Release; 2010 Jun; 144(2):251-8. PubMed ID: 20184933
[TBL] [Abstract][Full Text] [Related]
2. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
3. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells.
Heidenreich O; Krauter J; Riehle H; Hadwiger P; John M; Heil G; Vornlocher HP; Nordheim A
Blood; 2003 Apr; 101(8):3157-63. PubMed ID: 12480707
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8.
Matsushita H; Kizaki M; Kobayashi H; Muto A; Ikeda Y
Br J Cancer; 1999 Mar; 79(9-10):1325-31. PubMed ID: 10188872
[TBL] [Abstract][Full Text] [Related]
5. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells.
Simard P; Leroux JC
Int J Pharm; 2009 Nov; 381(2):86-96. PubMed ID: 19446624
[TBL] [Abstract][Full Text] [Related]
6. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21).
Matsushita H; Kobayashi H; Mori S; Kizaki M; Ikeda Y
Biochem Biophys Res Commun; 1995 Oct; 215(2):431-7. PubMed ID: 7487974
[TBL] [Abstract][Full Text] [Related]
7. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
[TBL] [Abstract][Full Text] [Related]
8. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
Wang XL; Xu R; Lu ZR
J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
[TBL] [Abstract][Full Text] [Related]
9. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
10. Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia.
Sacchi N; Schiaffonati L; Magnani I; Pappalardo C; Hughes AJ; Darfler M; Hoogeveen AT
Oncogene; 1996 Jan; 12(2):437-44. PubMed ID: 8570222
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
13. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
Li SD; Huang L
Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
[TBL] [Abstract][Full Text] [Related]
15. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
16. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.
Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY
Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631
[TBL] [Abstract][Full Text] [Related]
17. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
Liu S; Shen T; Huynh L; Klisovic MI; Rush LJ; Ford JL; Yu J; Becknell B; Li Y; Liu C; Vukosavljevic T; Whitman SP; Chang KS; Byrd JC; Perrotti D; Plass C; Marcucci G
Cancer Res; 2005 Feb; 65(4):1277-84. PubMed ID: 15735013
[TBL] [Abstract][Full Text] [Related]
18. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
Alshamsan A; Hamdy S; Samuel J; El-Kadi AO; Lavasanifar A; Uludağ H
Biomaterials; 2010 Feb; 31(6):1420-8. PubMed ID: 19913908
[TBL] [Abstract][Full Text] [Related]
19. [Acute myelogenous leukemia with ins(21;8) expressing AML-1-MTG8 fusion transcript].
Kazama H; Aoyama M; Sameshima Y; Teramura M; Masuda M; Motoji T; Okada M; Mizoguchi H
Rinsho Ketsueki; 1996 Nov; 37(11):1297-302. PubMed ID: 8960665
[TBL] [Abstract][Full Text] [Related]
20. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
